Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05712902 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Completion date: May 6, 2024 to Dec 31, 2025 Interventions: DZD9008 (Drug) to Sunvozertinib (Drug) · Eligibility criteria revised · Study title expanded, about 2 wordsv2 Show 3 more changesShow less
    • Interventions: DZD9008 (Drug) to Sunvozertinib (Drug)
    • Eligibility criteria revised
    • Study title expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase II, single-arm, multi-center clinical study to evaluate the anti-tumor efficacy, safety, tolerability and pharmacokinetics of Sunvozertinib in participants with locally advanced or metastatic NSCLC carrying EGFR exon 20 insertion mutations whose disease has progressed on prior platinum-based chemotherapy
Trial Details
NCT Number NCT05712902
Lead Sponsor Dizal Pharmaceuticals
Conditions Non-Small Cell Lung Cancer
Enrollment 104 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov